You must select a month AND year to filter.

 
  • ASH Volunteers Recount Rewarding Experiences Overseas
  • September 1, 2010

  • As ASH expands its global presence, the Society’s members find greater opportunities to contribute to the hematology community. Through a partnership with Health Volunteers Overseas (HVO), a nonprofit organization dedicated to improving global health through education, ASH members can share their hematology expertise by teaching clinicians and laboratory scientists in Uganda, Peru, and Cambodia. ASH member HVO volunteers provide education through day-to-day training, making a sustainable difference at the hospitals where they serve.

  • Headlines From Washington - September October 2010
  • September 1, 2010

  • HHS Announces Final Rules to Expand Use of Electronic Health Records

     

    CMS Releases Proposed 2010 Regulations Affecting Physician Payment

     

    FY 2011 NIH Funding Process Moves Forward

     

    FDA Announces Reorganization of the Office of Oncology Drug Products

     

    NIH Announces Availability of Educational Loan Repayment Programs

     

  • MicroRNAs in Hematologic Malignancy
  • September 1, 2010

  • MicroRNAs (miRNAs) are small non-coding RNAs of about 18 to 24 nucleotides in length that regulate gene expression and thus influence such processes as development, differentiation, proliferation, and apoptosis.1 MiRNAs exert their biological effects by binding in a sequence-specific manner for the most part to the 3’ untranslated region (3’ UTR) of the target mRNA, causing protein translation inhibition and/or mRNA degradation. It has been estimated that miRNAs regulate about 30 percent of human genes.1 Findings over the past eight years strongly support a role for deregulated miRNA activity in the initiation and progression of cancer, including hematologic malignancies (HM).1 We will briefly summarize the state of the field and discuss future directions.

  • Enhancing Clinical Trials Accrual Requires Changes in the Governmental Conference Room and Exam Room
  • September 1, 2010

  • Clinical research in hematology has never been more important, yet clinical investigators are facing unprecedented challenges. Constantly changing (and at times inconsistent) regulations, chaotic reimbursement policies, increasing demands on physician time, and scientific advances demonstrating the complex differences among individual patients all complicate hematology clinical research.

  • Tired Blood: How Stored RBCs Can Promote Inflammation Mediated by Iron
  • September 1, 2010

  • Red blood cell (RBC) transfusions are lifesaving procedures for severe blood loss, but needless transfusions performed on anemic euvolemic patients may be detrimental. Clinical trials restricting transfusions improved clinical outcomes in acutely ill individuals. Prolonged storage of RBCs (> 14-21 days before transfusion) increases mortality, infections, inflammation, and multi-organ failure.

  • Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Passing the Baton
  • September 1, 2010

  • The IRIS study and its companion long-term analyses established the natural history of imatinibtreated newly diagnosed chronic-phase (CP) CML. The trial cemented the importance of achieving an early complete cytogenetic response (CCR) and major molecular remission (MMR) — therapeutic milestones that translate into excellent long-term responses. No patients who achieved an MMR by 18 months progressed to the accelerated or blast phase. With eight years of follow-up, 85 percent of patients remain alive, the estimated event-free survival is 81 percent, and freedom from progression to advanced CML is 92 percent. Annual rates of progression to advanced CML remain less than 0.5 percent after five years.

  • Optimizing the Dose for Prophylactic Platelet Transfusions: Will PLADO Shape the Future of Transfusion Practice?
  • September 1, 2010

  • The fear of catastrophic hemorrhage during severe hypoproliferative thrombocytopenia compels physicians to act preemptively with prophylactic platelet transfusions. Without additional risk factors, spontaneous bleeding increases significantly at platelet counts < 5 x 109/L. The current accepted prophylactic platelet transfusion trigger of ≤ 10 x 109/L derives from multiple randomized, prospective platelet transfusion trials and reflects the use of standardized platelet concentrate doses (3 x 1011 to 6 x 1011 platelets for adults).

  • The Accident That Changed My Life: How an Engineer Got into Hematology Research
  • September 1, 2010

  • My entrée into hematology was a total accident. I arrived in the United States in 1968 with a degree in chemical engineering to begin graduate studies in the School of Engineering at Washington University, St. Louis. Having suddenly lost a mentor (though happily, not through carelessness) with whom I had started on my doctoral dissertation on properties of gases at high temperatures, I had to quickly find a new topic for my dissertation.

  • ASH-SAP 4th Edition Now Available for Purchase
  • September 1, 2010

  • The American Society of Hematology Self-Assessment Program (ASH-SAP) is an educational resource that brings together the latest advances in the ever-evolving disciplines of adult and pediatric hematology. This comprehensive publication, created for hematologists and others working in hematology-related fields, features informative content, thorough board and recertification preparation, and AMA PRA Category 1 Credits™.

  • 2010 MMSAP Participants
  • September 1, 2010

  • The Minority Medical Student Award Program (MMSAP) encourages minority medical students to pursue an interest in hematology research. For an eight- to 12-week period, MMSAP participants will work closely with their mentors on a hematology-related research project. The subjects investigated by this year’s students include thrombotic thrombocytopenic purpura (TTP), sickle cell anemia, MDS, and acute myeloid leukemia. The awardees will have the opportunity to present the results of their research at ASH’s annual meeting in December.

  • Oral Anticoagulation
  • September 1, 2010

  • Apixaban Versus Enoxaparin for Thromboprophylaxis After Knee Replacement (ADVANCE-2): A Randomized Double-Blind Trial

  • Register for ASH Webinar Series on Thrombosis
  • September 1, 2010

  • ASH will present a series of three webinars on thrombosis issues practicing hematologists frequently confront. The sessions, moderated by Dr. Mark Crowther, of Aberdeen Royal Infirmary, United Kingdom, will feature presentations by experts in the field, provide time for questions and answers, and cover the most current information on how to best diagnose and care for patients. All webinars will be one hour in length and occur at 8:00 p.m. (EST).

  • Joint Society Symposia
  • September 1, 2010

  • One of the privileges of being ASH president is the opportunity to represent our Society at other organizations’ meetings where we have the opportunity to bring a “taste of ASH” to researchers and clinicians in related disciplines. Whenever I attend these meetings, I am struck by the scientific and clinical diversity of our membership, the breadth of impact that hematologists have in related fields, and the respect that ASH and its members engender all around the world. Our global reach has grown significantly during this past year; we have a number of joint and ongoing efforts with the European Hematology Association (EHA), and we have extended our renowned Highlights of ASH® programs internationally.

  • Chronic Lymphocytic Leukemia
  • September 1, 2010

  • Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)

  • Myelodysplastic Syndrome
  • September 1, 2010

  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload (TELESTO)

< Prev Next > Page 1 of 111